姑息性放射治疗试验中的临床终点:一项系统性的元研究分析
该元研究分析检索了1990—2020年发表的姑息性放射治疗临床试验,共纳入292项。已发表试验中仅45.5%(66/145)采用以患者为中心的主要终点,17.3%(25/145)采用以肿瘤为中心的主要终点;已注册在研试验中以患者为中心主要终点的比例为32.8%(22/67)。
要点
- 仅64.4%(145/225)的已发表试验明确陈述了主要终点。
- 已发表试验中以患者为中心的主要终点占45.5%(66/145),以肿瘤为中心的占17.3%(25/145)。
- 已注册在研试验中以患者为中心的主要终点占32.8%(22/67),低于已发表试验。
核心结论
- 以患者为中心的主要终点在已发表的姑息性放射治疗试验中相对常见,但其使用仍不理想,且在目前在研试验中似乎更低。
研究设计与样本
- 预注册的元研究分析,检索Pubmed/MEDLINE、EMBASE、CENTRAL和ClinicalTrials.gov,纳入1990—2020年发表的姑息性放射治疗临床试验,共筛选7379条记录、292项符合条件。
- 终点分为以患者为中心的终点(包括总生存和患者报告结局)、以肿瘤为中心的终点(如局部控制)及其他终点(包括毒性和观察者评定的症状)。
- 采用描述性统计总结数据,并用逻辑回归评估发表年份是否预测主要终点的选择。
主要发现
- 试验的特征为样本量小,以及使用外照射放射治疗转移灶或胸部原发灶;患者中位年龄为64岁,中位ECOG为1。
- 仅64.4%(145/225)的已发表试验明确陈述了主要终点。
- 已发表试验中,以患者为中心的主要终点占45.5%(66/145),以肿瘤为中心的主要终点占17.3%(25/145)。
- 以患者为中心的主要终点使用随时间无统计学显著趋势。
- 已注册在研试验中,以患者为中心的主要终点占32.8%(22/67),以肿瘤为中心的主要终点占26.9%(18/67)。
关键数值与推荐
- 已发表试验明确陈述主要终点的比例为64.4%(145/225)。
- 已发表试验以患者为中心的主要终点为45.5%(66/145),以肿瘤为中心的主要终点为17.3%(25/145)。
- 已注册在研试验以患者为中心的主要终点为32.8%(22/67),以肿瘤为中心的主要终点为26.9%(18/67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Up to 50% of radiotherapy courses are delivered in palliative intent for various indications. Despite the large number of treated patients, we know little about the choice of endpoints in trials of palliative radiotherapy. Our primary aim was, therefore, to analyze primary endpoints in trials of palliative radiotherapy. METHODS: We conducted a pre-registered (https://doi.org/10.17605/OSF.IO/GMCAF) meta-research analysis searching Pubmed/MEDLINE, EMBASE, CENTRAL, and "ClinicalTrials.gov" for clinical trials of palliative radiotherapy published 1990-2020. Endpoints were categorized in "patient-centered endpoints", including overall survival and patient-reported outcomes, and "tumor-centered endpoints" such as local control. The remainder were "other endpoints" including toxicity or observer-rated symptoms. We applied descriptive statistics to summarize data and logistic regression to assess if year of publication predicted the choice of primary endpoints. RESULTS: Of 7379 records screened, 292 were eligible. Trials were characterized by small sample sizes and use of external beam radiotherapy for metastases or thoracic primaries. Median patient age was 64 and median ECOG was 1. Only 64.4%(145/225) of published trials clearly stated their primary endpoint. Published trials employed a "patient-centered primary endpoint" in 45.5%(66/145) and a "tumor-centered primary endpoint" in 17.3%(25/145) of the cases. There was no statistically significant trend in time for the use of "patient-centered primary endpoints". Registered ongoing trials used a "patient-centered primary endpoint" in 32.8%(22/67) and a "tumor-centered primary endpoint" in 26.9%(18/67) of the cases. CONCLUSION: Although "patient-centered primary endpoints" appear relatively prevalent in published trials of palliative radiotherapy, their use is still suboptimal and appears to be lower in currently ongoing trials.
引用
- Fabian A, Domschikowski J, Letsch A, et al. Clinical endpoints in trials of palliative radiotherapy: A systematic meta-research analysis. Radiother Oncol. 2022. PMID: 35868602. doi:10.1016/j.radonc.2022.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。